The most frequent tumor associated with CDH1 germline mutations was BC (33/54, 61.1%), following prostate cancer (PC) (9/54, 16.7%), CRC (7/54, 12.9%), abdominal carcinosis (Ca) (2/54, 3.7%), ovarian cancer (OC) (1/54, 1.8%), thyroid cancer (ThC) (1/54, 1.8%), and tongue cancer (ToC) (1/54, 1.8%) (Figure 1). This evidence concerns the gene CDH1 and prostate carcinoma.